Background Polyacrylamide gel (PAAG) was first manufactured in Ukraine in the late 1980s and introduced as a biomaterial for ''breast augmentation without surgery.'' Since it is prohibited in most countries, PAAG injections are rare nowadays, but their consequences and long-term complications can be crucial. Methods We identified 106 patients consecutively operated on for PAAG complications at three teaching Ukrainian hospitals between 1998 and 2009. All relevant sociodemographic, clinical, and treatment characteristics were collected. Forty-five (42%) patients were available for clinical follow-up. Results The majority (88%) had had bilateral PAAG injections. The mean volume of injected PAAG was 230 ml/breast (range = 50-400). Mean age at injection was 29 years (range = 17-49) and the mean time from the injection to complications was 6.1 years (SD = 4.1). Symptoms preceding debridement were pain in 85 patients (80%), breast hardening in 79 (74%), breast deformity in 77 (73%), lumps in 57 (54%), gel migration in 39 (37%), fistulas in 17 (16%), and gel leakage in 12 (11%). The surgical interventions in 199 breasts included gel evacuation alone in 107 (54%) or in combination with partial mastectomy in 65 (33%), partial mastectomy and partial pectoralis muscle resection in 12 (6%), or subcutaneous mastectomy in 15 (7%). Of the 199 operated breasts, 86 (43%) immediate and 58 (29%) delayed implant-based breast reconstructions were performed. Conclusion Injections of PAAG can cause irreversible damage to the breast necessitating complex debridement procedures, even mastectomy and breast reconstruction. Despite numerous surgical interventions, gel remnants are still found on subsequent breast imaging. Although PAAG is prohibited in many countries, different types of Electronic supplementary material The online version of this article
injections with unknown long-term effects are currently being used. Making the public aware of the problems of injectables for breast augmentation is warranted.
Introduction
There have been numerous attempts to find the optimal biomaterial for safe and easy breast augmentation. Paraffin, petrolatum, vegetable oil, lanolin, beeswax, bioplax, and liquid silicone are examples that initially seemed promising, but in the long term all led to unfavorable results with serious side effects [1] .
Polyacrylamide gel (PAAG) for breast augmentation was first manufactured in Ukraine in the late 1980s under the name ''Interfall'' and introduced as a biomaterial for ''tissue augmentation without operation'' that could be performed either in the outpatient setting under local anesthesia or in the operating room under general anesthesia. PAAG is a jellylike transparent substance containing about 5% polyacrylamide and more than 95% water. Polyacrylamide in this compound has not been shown to be toxic or carcinogenic in several animal studies [2] .
The injection of PAAG was quickly adopted in other countries. Supposedly, thousands of women in Asia have undergone breast augmentation with PAAG during the last decade [3, 4] . PAAG has also been utilized for soft tissue augmentation in several countries of the European Union and in the US [5] [6] [7] [8] [9] . Unfavorable results leading to debridement operations have only been scarcely reported; however, PAAG injections have been shown to be potentially dangerous, causing substantial irreversible damage to the breasts in previously healthy women [4, 10] . The most common complications are painful lumps and breast hardening, followed by gel migration that can spread outside the breast contour [11] . Since PAAG injections are prohibited in most countries they are rare nowadays, but their consequences and long-term complications can be crucial.
With the introduction and increasing popularity of other injectable biomaterials as well as adipose tissue (i.e., lipofilling), evaluation of long-term results is much needed. To date, there are no outcome studies evaluating PAAG injections or any descriptive algorithm for the management of PAAG complications.
The primary aim of this study was to describe a large cohort of patients with a wide spectrum of complications after PAAG injections. The secondary aim was to evaluate the outcomes of debridement operations, focusing on the management and different approaches to breast restoration, and the patients' health-related quality of life and satisfaction.
Methods

Study design
We conducted a descriptive retrospective multicenter study of consecutively operated on patients with a prospective clinical follow-up evaluation.
Patients and data collection
All women who presented with complications after PAAG injections for breast augmentation at three teaching hospitals in Ukraine from February 1998 to September 2009 were eligible. The PAAG injections had been performed elsewhere and all patients were self-referred. All debridement procedures were free of charge, whereas implants used for breast reconstruction were not covered by the health-care system. Patients were informed by the treating physician that complete PAAG removal would not always be possible and they were encouraged to come back if symptoms remained.
Patients were identified through use of an operating room logbook where all surgical procedures performed at each of the three departments were registered. The data included the patient's medical chart number, diagnosis, and date and type of operation. The archive was searched by date of operation and medical chart number. The inclusion criterion was if the patient had a revision procedure following PAAG injections. Patients without sufficient medical documentation, i.e., unavailable or incomplete medical or surgical records, were excluded. All relevant clinical records from three teaching hospitals in Ukraine were reviewed. A study database was constructed and included variables such as date of birth, date of injection, volume of injected gel, injection site, symptoms at presentation, patient's BMI at debridement operation, and dates and types of reoperations. Available sociodemographic data were extracted and stored in a separate electronic database.
Clinical follow-up
An introductory letter with an invitation to participate in the follow-up study was sent to the patients together with a prepaid return envelope. If no response was obtained within 1 month, patients were contacted by phone. In addition, all invited patients were offered a free breast ultrasound examination and a consultation with a plastic surgeon. Women were seen in one of the three outpatient clinics between February 2010 and September 2010 by three of the coauthors (DU, VK, GP). The consultation included current medical history, breast inspection, symmetry measurement (sternal notch to nipple, nipple to midline, and nipple to submammary fold), breast ultrasonography, and photo documentation.
Patient-reported outcome measures
At follow-up patients were asked to fill in study questionnaires, which included EQ-5D, an aesthetic outcome questionnaire, and a study-specific questionnaire. The EQ-5D questionnaire is a validated and globally used non-diseasespecific instrument that measures health-related quality of life. It consists of two parts: the EQ-5D descriptive system and the EQ visual analog scale (EQ-VAS). Each of the five dimensions in the EQ-5D descriptive system (mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression) has three levels: no problems, some problems, and severe problems. EQ-VAS is a vertical visual analog scale for self-rating the current health-related quality of life (HRQoL) ranging from zero (''worst imaginable health state'') to 100 (''best imaginable health state'') [12, 13] .
The aesthetic outcome questionnaire consisted of four structured questions that assessed satisfaction with the size, shape, symmetry, and sensibility of the breast. Each assessment was scored in seven categories from one (''very bad'') to seven (''very good'') [14] . Patients were also asked to rate their intensity of pain on a horizontal scale of 100 mm with descriptors ''no pain'' and ''very severe pain'' at each end [15] .
Finally, a study-specific questionnaire was designed to collect extended sociodemographic data and details about the PAAG injection.
Statistics
Descriptive data are presented in the tables as number of cases and frequencies [n (%)]. Mean values with a range (min-max) or standard deviation (SD) were used when appropriate. EQ-5D was analyzed according to the manual [13] . VAS score was measured and reported in millimeters. Breast symmetry was presented as a mean paired difference between distances on the right and left sides. In the aesthetic results questionnaire, satisfaction with the breast characteristics was categorized as ''negative'' (1-3), ''neutral'' (4), or ''positive'' (5-7). 
Results
One-hundred fifteen patients were identified in the operation room logbooks as having undergone breast surgery for complications after PAAG injections. Charts for nine patients were unavailable and therefore excluded. Onehundred six patients were eligible and thus included in the study. Their mean age at the debridement operation was 35 years (range = 20-56). At presentation, the majority of patients, 93 (88%), had had bilateral PAAG injections, and the total number of breasts with PAAG was 199. The mean volume of injected PAAG reported by 50 patients was 230 ml/breast (range = 50-400). Patients' mean age at injection was 29 years (range = 17-49).
Patients' symptoms at presentation were pain in 85 (80%), breast hardening in 79 (74%), breast deformity in 77 (73%), lumps in 57 (54%), gel migration in 39 (37%), fistulas in 17 (16%), and gel leakage in 12 (11%). The majority of patients, 84 (80%), presented with three or more symptoms ( Table 1) . Examples of complications are illustrated in Fig. 1 .
For extended sociodemographic characteristics and PAAG injection details see Supplementary Table 1 .
Surgical treatment and breast reconstruction
The mean time between the injection and the debridement operation was 51 months (range = 2-160). All operations were performed under general anesthesia. Preoperatively, patients routinely underwent ultrasonography of the breast in order to localize gel deposits. All visible or palpable gel deposits within the glandular or muscular tissues were drained and/or excised. The primary debridement procedures included PAAG evacuation alone in 107 (54%) breasts or in combination with partial mastectomy in 65 (33%), partial mastectomy and partial pectoralis muscle resection in 12 (6%), or subcutaneous mastectomy in 15 (7%). Submammary incisions were used in 88 (83%) patients as the method of choice, allowing both wide tissue dissection and better visualization. When necessary, additional incisions were made to evacuate migrated gel or to excise the fistulas ( Table 2 ). The gel was evacuated through the open wound using a suction system, with further rinsing with saline or furacilin solution.
Forty-three (41%) patients underwent immediate breast reconstruction concurrently with debridement surgery and 29 (27%) received delayed breast reconstruction. Permanent implants with a mean volume of 320 ml (range = 190-440) were used in all cases of breast reconstruction. When possible, implants were placed under the pectoralis major muscle. The average hospital stay was 4 days (range = 1-11), and in all but three patients breast drains were used and kept in place for 3 days (range = 1-7) postoperatively. Forty-eight (45%) patients required reoperation following the primary debridement operation: 15 (14%) had one reoperation, 26 (24%) two, and 7 (7%) three or more reoperations. Apart from delayed breast reconstruction, reoperations comprised gel-related revision surgeries as well as implant-related interventions. The mean number of operations required for each breast during the follow-up was 1.8 (range = 1-4). Clinical follow-up examination and questionnaires Forty-five (42%) patients were available for follow-up: 31 patients were seen in the outpatient clinic and 14 patients were interviewed by phone. The mean follow-up time after debridement surgery was 4.6 years (range = 1.2-12.0).
Patients were asked about present breast-related complaints and 22/45 reported one or more of the following problems: asymmetry/aesthetic problems (n = 15), breast hardening (n = 12), scars (n = 8), lumps (n = 2), and pain (n = 1). Breast ultrasonography revealed gel remnants in 37/60 (62%) breasts.
Although no statistically significant difference between right and left side was found (data not shown), 15 (54%) patients had a C1 cm difference at any of the three points of measure.
Health status (EQ-5D)
The EQ-5D self-report questionnaire was answered by 37 patients. The questionnaire revealed that 95, 97, and 100% of the patients had no problems with usual activities, mobility, and self-care, respectively. Anxiety/depression and pain/discomfort dimensions were reported as problematic by 32 and 19%, respectively (Table 3) . Thus, 20 (54%) women reported full health, i.e., no problems within any of the five dimensions. Mean score of the subjective evaluation of HRQoL on EQ-5D VAS was 80 (range = 50-100).
Breast-related pain intensity assessment Fifteen (41%) patients reported ''no pain.'' The median score on the 100-mm pain intensity scale was 3 mm, varying from 0 to 65 mm.
Satisfaction with the aesthetic outcome
The majority of responders, 86%, were satisfied with the breast size, whereas items like breast softness, symmetry, sensitivity, and shape were rated positively by 64, 65, 69, and 54%, respectively (Table 4) .
Discussion
This study found that PAAG injections for breast augmentation could lead to severe complications, necessitating multiple debridement operations and sometimes partial or total mastectomy with breast reconstruction.
PAAG injections in Ukraine for tissue enlargement have been performed predominantly in private hospitals by trained physicians. In the 1990s, it was believed to be a promising method for breast augmentation. Both unsatisfactory outcome and prohibition of the use of PAAG terminated the PAAG era. Nevertheless, PAAG is still occasionally used in rural areas of Ukraine. Complications following PAAG injections occurred early and late. The majority of our patients presented late, with a mean time from injection to debridement of 6 years. We have no clear explanation for this fact. Speculatively, patients may have sought other hospitals previously. We were unable to obtain information on the duration of symptoms.
Several image modalities like ultrasonography, mammography, and magnetic resonance imaging (MRI) can ascertain gel distribution in the breast. In most cases, gel deposits are located in front of the pectoralis muscle (the retromammary space). Some patients present with gel probably having been injected behind the pectoralis fascia and even into the glandular tissue. Ultrasonography has diagnostic value and is usually sufficient to identify multiple anechoic areas throughout the whole breast gland and within the pectoralis major muscle [16] . MRI appears to be even more sensitive and reveals intramuscular PAAG deposits not seen on ultrasound [17, 18] .
A study by Qiao et al. [10] concluded that among 30 patients with complications, 93% had lumps, 67% had pain, 27% had infection and 15% had firmness, breast disfigurement. Other studies [19, 20] showed that lumps and indurations were most prevalent, adding breast asymmetry and gel displacement to the list of complications. Christensen et al. [8] listed the reasons for reoperation among 27 patients as follows: inflammation (n = 7), injury (n = 6), lumps (n = 6), asymmetry (n = 4), and ptosis (n = 2), and noted that inflammation and injury were not related to the gel injection. In a recent Chinese publication, Cheng et al. [3] described specific complications like hematoma, seroma, and galactocele after PAAG injection in 28/2,610 women. The overall complication rate amounted to 20%; however, this was not specifically described further. The authors nevertheless strongly advise that PAAG is unsuitable for breast augmentation. In this study, pain was the major complaint. More than half of the patients presented with multiple complaints, including pain, breast deformity, lumps, and breast hardening. Moreover, PAAG migration was found in every third patient. This could be related to the volume of the gel injected and to the longer follow-up and time from injection to presentation in our cohort.
Most reports conclude that complete gel evacuation using aspiration is impossible as there is still residual gel in the breast tissue, even after several suction procedures [10] . An open debridement operation permits removal of as much gel as possible and often also removal of glandular tissue, whereby a subsequent breast reconstruction will be necessary to restore the breast shape. Almost half of the patients in our study required one or more reoperations following debridement, and breast reconstruction had to be performed in the majority of the cases. The skin envelope was preserved in all cases, which made implant reconstruction possible. In our experience, a two-stage procedure with initial debridement followed by delayed breast reconstruction is preferable, especially in cases where the gel has migrated within the breast gland and into the pectoralis muscle. We inform patients that further gel-related reoperations may be indicated and recommend a secondstage breast reconstruction. However, we found that these women are highly reluctant not to undergo immediate breast reconstruction, i.e., concurrently with the removal of the gel.
Despite repeated interventions, patients still had imagedetected deposits of PAAG at follow-up, although not symptomatic. Freely injected biomaterials make breast imaging difficult and thus a breast malignancy can be missed. There is no information on whether breast cancer diagnosis has been delayed in patients with PAAG injections. PAAG-injected women tend to be in an age category where breast cancer is less prevalent. However, if gel remnants are still present, this may challenge future breast imaging. Recently published case reports also describe cases of breast cancer in women after PAAG injection and assume a possible association [21] [22] [23] .
Patients reported satisfactory HRQoL, and though we were unable to find EQ-5D normative data for Ukrainian women, the reported outcomes were consistent with the normative data for the general population of women in Poland [24] . Anxiety/depression and pain/discomfort were the two dimensions of EQ-5D where patients reported some problems.
The vast majority of patients were satisfied with their breast size but only 54% with the breast shape. The latter could be explained by the mutilating effect of the gel on the glandular tissue, where gel migration and subsequent debridement affect the shape of the breast. When women were asked specifically about breast pain intensity, the majority scored their pain very low despite extensive revisions and remaining gel deposits.
There are hitherto no published series on the outcome after PAAG injections. PAAG injection and subsequent complication-related surgical interventions are seldom performed within the same institutions, making follow-up difficult.
The strengths of our study are that patients from three hospitals are included, making this the largest published series on this topic thus far. In addition, there was a consistency in the management of complications that facilitated the pooling of data.
A weakness of the study is that we have no control group of women who underwent ''successful'' PAAG injections and thus we cannot define the magnitude of the problem. Another weakness is the low response rate in the follow-up study.
In conclusion, injections of PAAG for breast augmentation may cause irreversible damage to the breast in healthy women necessitating complex debridement operations and even breast reconstruction. Despite numerous surgical interventions, gel remnants are still found upon subsequent breast imaging. Although PAAG is prohibited in many countries, different types of injections with unknown long-term effects are currently being used. Making the public aware of the problems of injectables for breast augmentation is warranted.
